Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $9.27 and last traded at $9.27, with a volume of 1017927 shares traded. The stock had previously closed at $10.05.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, November 19th. Jefferies Financial Group assumed coverage on Rocket Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $29.00 target price on the stock. Wedbush began coverage on Rocket Pharmaceuticals in a report on Monday, December 30th. They set an "outperform" rating and a $32.00 price target for the company. Canaccord Genuity Group reissued a "buy" rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Chardan Capital dropped their target price on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.64.
Read Our Latest Stock Report on RCKT
Rocket Pharmaceuticals Stock Performance
The firm has a market capitalization of $846.85 million, a price-to-earnings ratio of -3.38 and a beta of 0.98. The firm's 50-day moving average price is $10.94 and its two-hundred day moving average price is $14.78. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. Sell-side analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in RCKT. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Rocket Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock worth $61,000 after purchasing an additional 582 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Rocket Pharmaceuticals by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,505 shares of the biotechnology company's stock worth $323,000 after buying an additional 6,839 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Rocket Pharmaceuticals by 22.2% during the third quarter. Rice Hall James & Associates LLC now owns 92,142 shares of the biotechnology company's stock worth $1,702,000 after buying an additional 16,719 shares in the last quarter. VELA Investment Management LLC raised its stake in shares of Rocket Pharmaceuticals by 49.0% in the third quarter. VELA Investment Management LLC now owns 30,959 shares of the biotechnology company's stock valued at $572,000 after acquiring an additional 10,186 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Rocket Pharmaceuticals by 73.5% in the third quarter. Harbor Capital Advisors Inc. now owns 168,506 shares of the biotechnology company's stock valued at $3,112,000 after acquiring an additional 71,372 shares during the last quarter. 98.39% of the stock is owned by institutional investors.
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Articles
Before you consider Rocket Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.
While Rocket Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
